SAGE Open Medical Case Reports (May 2021)

Iliopsoas hematoma in patients with COVID-19 on low-molecular-weight heparin treatment

  • Gianluca Sottilotta,
  • Carmelo Mangano,
  • Rosa Basile,
  • Carmela Falcone,
  • Francesca Luise,
  • Demetrio Megalizzi,
  • Giovanna Maria Nicolò,
  • Vincenzo Oriana,
  • Angela Piromalli

DOI
https://doi.org/10.1177/2050313X211016991
Journal volume & issue
Vol. 9

Abstract

Read online

Patients with COVID-19 are at high risk of thromboembolic events; for this reason, the use of heparin is largely recommended but, in addition to thrombotic complications, bleeding is a significant cause of morbidity in patients with COVID-19. Idiopathic iliopsoas hematoma is a very rarely described hemorrhagic complication in patients with COVID-19. We report here two cases of iliopsoas hematoma in male patients with COVID-19 and being treated with heparin.